Arbitration courts established to resolve conflicts between patents and generic or reference medicaments do not have jurisdiction to decide on the validity of the patent, even when it is argued as a defence in an action for infringement. Transferring the authorization to introduce a generic medicament in the market to a third party is not, in itself, an infringement to the exclusive right granted by the patent and therefore is not prohibited in the scope of the arbitration provided for under Law No 62/2011.
A full summary of this case has been published on Kluwer IP Law.
________________________
To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.
